Absci is trading at $11.72, up 5.87%, with no verified October 5 company announcement or report directly explaining the move.
- Absci’s latest identified company release outlined Phase 2 STORYLINE trial plans on September 24, before this session.
- The S&P 500 is up 0.86% and the NASDAQ Composite is up 1.28%; the gain may reflect broader risk-on sentiment, though that link is unconfirmed.
- Trading-volume details were unavailable.